JP2015520238A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520238A5 JP2015520238A5 JP2015518539A JP2015518539A JP2015520238A5 JP 2015520238 A5 JP2015520238 A5 JP 2015520238A5 JP 2015518539 A JP2015518539 A JP 2015518539A JP 2015518539 A JP2015518539 A JP 2015518539A JP 2015520238 A5 JP2015520238 A5 JP 2015520238A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound
- stereoisomer
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 50
- 150000003839 salts Chemical class 0.000 claims 37
- 125000000753 cycloalkyl group Chemical group 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 201000000980 schizophrenia Diseases 0.000 claims 11
- 208000028017 Psychotic disease Diseases 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 10
- 125000003342 alkenyl group Chemical group 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 9
- 125000004404 heteroalkyl group Chemical group 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 8
- 125000001475 halogen functional group Chemical group 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000004103 aminoalkyl group Chemical group 0.000 claims 6
- 208000010877 cognitive disease Diseases 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 6
- 150000003573 thiols Chemical class 0.000 claims 6
- 208000028698 Cognitive impairment Diseases 0.000 claims 5
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 208000022821 personality disease Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 230000000698 schizophrenic effect Effects 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 208000017194 Affective disease Diseases 0.000 claims 1
- 206010001497 Agitation Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 208000024254 Delusional disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010018612 Gonorrhoea Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010033864 Paranoia Diseases 0.000 claims 1
- 208000027099 Paranoid disease Diseases 0.000 claims 1
- 208000027465 Psychotic Affective disease Diseases 0.000 claims 1
- 206010061921 Psychotic disorder due to a general medical condition Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 206010070834 Sensitisation Diseases 0.000 claims 1
- 208000019568 Shared Paranoid disease Diseases 0.000 claims 1
- 208000028810 Shared psychotic disease Diseases 0.000 claims 1
- 208000011963 Substance-induced psychotic disease Diseases 0.000 claims 1
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 1
- 208000021017 Weight Gain Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000016571 aggressive behavior Effects 0.000 claims 1
- 238000013019 agitation Methods 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- -1 amino, imino Chemical group 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 201000003104 endogenous depression Diseases 0.000 claims 1
- 230000002964 excitative effect Effects 0.000 claims 1
- 208000001786 gonorrhea Diseases 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 1
- 125000003367 polycyclic group Chemical group 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 208000012672 seasonal affective disease Diseases 0.000 claims 1
- 230000008313 sensitization Effects 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
- 0 C*c1n[n](*I)c(C)c1C Chemical compound C*c1n[n](*I)c(C)c1C 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261661710P | 2012-06-19 | 2012-06-19 | |
| US61/661,710 | 2012-06-19 | ||
| PCT/US2013/046483 WO2013192273A1 (en) | 2012-06-19 | 2013-06-19 | Heteroaryl compounds and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017174559A Division JP6422542B2 (ja) | 2012-06-19 | 2017-09-12 | ヘテロアリール化合物及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015520238A JP2015520238A (ja) | 2015-07-16 |
| JP2015520238A5 true JP2015520238A5 (enExample) | 2016-07-28 |
| JP6236439B2 JP6236439B2 (ja) | 2017-11-22 |
Family
ID=49769319
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015518539A Expired - Fee Related JP6236439B2 (ja) | 2012-06-19 | 2013-06-19 | ヘテロアリール化合物及びその使用方法 |
| JP2017174559A Expired - Fee Related JP6422542B2 (ja) | 2012-06-19 | 2017-09-12 | ヘテロアリール化合物及びその使用方法 |
| JP2018194979A Expired - Fee Related JP6786566B2 (ja) | 2012-06-19 | 2018-10-16 | ヘテロアリール化合物及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017174559A Expired - Fee Related JP6422542B2 (ja) | 2012-06-19 | 2017-09-12 | ヘテロアリール化合物及びその使用方法 |
| JP2018194979A Expired - Fee Related JP6786566B2 (ja) | 2012-06-19 | 2018-10-16 | ヘテロアリール化合物及びその使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US9505751B2 (enExample) |
| EP (1) | EP2861596B1 (enExample) |
| JP (3) | JP6236439B2 (enExample) |
| KR (1) | KR20150021120A (enExample) |
| CN (1) | CN104583210B (enExample) |
| AU (1) | AU2013277258B2 (enExample) |
| BR (1) | BR112014031798A2 (enExample) |
| CA (1) | CA2874180A1 (enExample) |
| IL (1) | IL235909A (enExample) |
| IN (1) | IN2015DN00345A (enExample) |
| MX (1) | MX374323B (enExample) |
| NZ (1) | NZ702239A (enExample) |
| RU (1) | RU2644558C2 (enExample) |
| SG (1) | SG11201408178TA (enExample) |
| WO (1) | WO2013192273A1 (enExample) |
| ZA (1) | ZA201408856B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3436461B1 (en) | 2016-03-28 | 2023-11-01 | Incyte Corporation | Pyrrolotriazine compounds as tam inhibitors |
| EP3856185A1 (en) | 2018-09-28 | 2021-08-04 | Takeda Pharmaceutical Company Limited | Balipodect for treating or preventing autism spectrum disorders |
| UA127747C2 (uk) | 2018-10-23 | 2023-12-20 | Басф Се | Трициклічні пестицидні сполуки |
| CN110386897A (zh) * | 2019-08-15 | 2019-10-29 | 上海毕得医药科技有限公司 | 一种4-氟-3-甲基吡啶-2-胺的合成方法 |
| MX2022006370A (es) | 2019-11-25 | 2022-09-07 | Amgen Inc | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso. |
| EP4136086A1 (en) | 2020-04-14 | 2023-02-22 | Basf Se | Tricyclic pesticidal compounds |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2274712B1 (es) * | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
| TW200815436A (en) | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| WO2009068320A1 (en) * | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 |
| TWI501965B (zh) * | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
| EP2318410A2 (en) * | 2008-07-09 | 2011-05-11 | Envivo Pharmaceuticals, Inc. | New small-molecule pde-10 inhibitors |
| TWI481607B (zh) * | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| TWI485151B (zh) * | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物 |
| TWI487705B (zh) * | 2009-12-17 | 2015-06-11 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物 |
| NZ603789A (en) * | 2010-05-26 | 2015-03-27 | Sunovion Pharmaceuticals Inc | Heteroaryl compounds and methods of use thereof |
| US20130203756A1 (en) * | 2010-10-29 | 2013-08-08 | Jamie L. Bunda | Isoindoline pde10 inhibitors |
| JO3089B1 (ar) | 2010-11-19 | 2017-03-15 | H Lundbeck As | مشتقات ايميدازول كمثبطات لانزيمات pde10a |
| CN107141309A (zh) * | 2011-01-11 | 2017-09-08 | 桑诺维恩药品公司 | 杂芳基化合物及其使用方法 |
| WO2012147890A1 (ja) * | 2011-04-27 | 2012-11-01 | 持田製薬株式会社 | 新規アゾール誘導体 |
| US8592423B2 (en) * | 2011-06-21 | 2013-11-26 | Bristol-Myers Squibb Company | Inhibitors of PDE10 |
| EP2733141B1 (en) * | 2011-07-15 | 2019-01-09 | Shionogi & Co., Ltd. | Azabenzimidazole derivative having ampk-activating activity |
| EP2763533B1 (en) * | 2011-10-06 | 2021-12-29 | Merck Sharp & Dohme Corp. | Triazolyl pde10 inhibitors |
-
2013
- 2013-06-19 CA CA2874180A patent/CA2874180A1/en not_active Abandoned
- 2013-06-19 JP JP2015518539A patent/JP6236439B2/ja not_active Expired - Fee Related
- 2013-06-19 EP EP13806923.2A patent/EP2861596B1/en not_active Not-in-force
- 2013-06-19 IN IN345DEN2015 patent/IN2015DN00345A/en unknown
- 2013-06-19 WO PCT/US2013/046483 patent/WO2013192273A1/en not_active Ceased
- 2013-06-19 KR KR1020157001398A patent/KR20150021120A/ko not_active Ceased
- 2013-06-19 NZ NZ702239A patent/NZ702239A/en not_active IP Right Cessation
- 2013-06-19 RU RU2014148110A patent/RU2644558C2/ru not_active IP Right Cessation
- 2013-06-19 AU AU2013277258A patent/AU2013277258B2/en not_active Ceased
- 2013-06-19 SG SG11201408178TA patent/SG11201408178TA/en unknown
- 2013-06-19 US US14/409,866 patent/US9505751B2/en not_active Expired - Fee Related
- 2013-06-19 BR BR112014031798A patent/BR112014031798A2/pt not_active Application Discontinuation
- 2013-06-19 CN CN201380032220.6A patent/CN104583210B/zh not_active Expired - Fee Related
- 2013-06-19 MX MX2014014751A patent/MX374323B/es active IP Right Grant
-
2014
- 2014-11-25 IL IL235909A patent/IL235909A/en active IP Right Grant
- 2014-12-03 ZA ZA2014/08856A patent/ZA201408856B/en unknown
-
2016
- 2016-10-20 US US15/298,469 patent/US9994590B2/en active Active
-
2017
- 2017-09-12 JP JP2017174559A patent/JP6422542B2/ja not_active Expired - Fee Related
-
2018
- 2018-05-11 US US15/977,166 patent/US10604536B2/en active Active
- 2018-10-16 JP JP2018194979A patent/JP6786566B2/ja not_active Expired - Fee Related